ifosfamide and Cancer of the Uterus studies

Research Excerpts

Excerpt	Relevance	Reference
"This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS)."	9.51	Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. ( Copeland, LJ; DiSilvestro, PA; Filiaci, VL; Hensley, ML; Huang, HQ; Ioffe, OB; Miller, DS; Moore, KN; Mutch, DG; Powell, MA; Santin, A; Secord, AA; Spirtos, NM; Tewari, KS; Warshal, DP, 2022)
"To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free survival (PFS), response, and toxicity."	9.12	Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. ( Bitterman, P; Eaton, L; Filiaci, V; Homesley, HD; Kilgore, LC; Markman, M; Monk, BJ; Ueland, FR, 2007)
"Adjuvant ifosfamide and cisplatin after primary surgery for stage I or II carcinosarcoma of the uterus is tolerable."	9.11	Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. ( Carson, LF; Gallion, H; Kauderer, J; Lentz, SS; Sutton, G; Whitney, CW, 2005)
"The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival."	9.09	A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. ( Brunetto, VL; Hsiu, JG; Kilgore, L; Lentz, SS; McGehee, R; Olt, G; Soper, JT; Sorosky, J; Sutton, G, 2000)
"This is a Phase II groupwide study of the Gynecologic Oncology Group (GOG) to determine the toxicity and efficacy of a combination of ifosfamide and doxorubicin in patients with advanced or metastatic leiomyosarcomas of the uterus who had not received other chemotherapy."	9.08	Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. ( Blessing, JA; Malfetano, JH; Sutton, G, 1996)
"A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma."	7.83	Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016)
"To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management."	7.76	Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010)
"To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas."	7.73	Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. ( Piura, B; Rabinovich, A, 2005)
" In this article we report the first case of methemoglobinemia in a patient with metastatic uterine leiomyosarcoma, after infusion of ifosfamide chemotherapy."	7.70	Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. ( Govert, JA; Hadjiliadis, D, 2000)
"Between 1992 and 1999, 13 consecutive patients with completely resected moderate- to high-grade uterine sarcoma received three cycles of adjuvant ifosfamide (1."	7.70	Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000)
"The purpose of this study was to evaluate the activity of ifosfamide (isophosphamide) in patients with advanced or recurrent leiomyosarcoma not previously exposed to chemotherapy."	7.68	Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. ( Barrett, RJ; Blessing, JA; McGehee, R; Sutton, GP, 1992)
"This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS)."	5.51	Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. ( Copeland, LJ; DiSilvestro, PA; Filiaci, VL; Hensley, ML; Huang, HQ; Ioffe, OB; Miller, DS; Moore, KN; Mutch, DG; Powell, MA; Santin, A; Secord, AA; Spirtos, NM; Tewari, KS; Warshal, DP, 2022)
" So we compared VAC protocol and ifosfamiide for toxic effects."	5.30	Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). ( Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998)
"Ifosfamide alone was given as a 24-h infusion at doses ranging from 5 to 7."	5.28	Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma. ( Hawkins, RE; Mansi, JL; Wiltshaw, E, 1990)
"To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free survival (PFS), response, and toxicity."	5.12	Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. ( Bitterman, P; Eaton, L; Filiaci, V; Homesley, HD; Kilgore, LC; Markman, M; Monk, BJ; Ueland, FR, 2007)
"Adjuvant ifosfamide and cisplatin after primary surgery for stage I or II carcinosarcoma of the uterus is tolerable."	5.11	Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. ( Carson, LF; Gallion, H; Kauderer, J; Lentz, SS; Sutton, G; Whitney, CW, 2005)
"The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival."	5.09	A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. ( Brunetto, VL; Hsiu, JG; Kilgore, L; Lentz, SS; McGehee, R; Olt, G; Soper, JT; Sorosky, J; Sutton, G, 2000)
"This is a Phase II groupwide study of the Gynecologic Oncology Group (GOG) to determine the toxicity and efficacy of a combination of ifosfamide and doxorubicin in patients with advanced or metastatic leiomyosarcomas of the uterus who had not received other chemotherapy."	5.08	Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. ( Blessing, JA; Malfetano, JH; Sutton, G, 1996)
"In advanced stage metastatic uterine carcinosarcoma as well as recurrent disease adjuvant combination, chemotherapy with ifosfamide should be considered."	4.89	Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. ( Bryant, A; Das, N; Galaal, K; Godfrey, K; Kucukmetin, A; Lopes, AD; Naik, R; van der Heijden, E, 2013)
" In the primary treatment/ first line therapy of advanced stage metastatic uterine carcinosarcoma, as well as in recurrent disease, adjuvant combination chemotherapy with ifosfamide and paclitaxel should be considered."	4.87	Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. ( Bryant, A; Galaal, K; Godfrey, K; Kucukmetin, A; Naik, R, 2011)
"A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma."	3.83	Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016)
"To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management."	3.76	Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010)
"Our study corroborates GOG 150 results, and shows that paclitaxel-carboplatin appears to be an efficacious adjuvant chemotherapy regimen for completely resected uterine carcinosarcoma."	3.74	A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. ( Abu-Rustum, NR; Aghajanian, CA; Alektiar, KM; Hensley, ML; Iasonos, A; Makker, V; Zhou, Q, 2008)
"Our data suggest a potential role for anthracycline- and ifosfamide-containing chemotherapy in the adjuvant setting for early-stage uterine sarcomas."	3.74	Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience. ( Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Markaki, S; Papadimitriou, CA; Rodolakis, A; Voulgaris, Z; Zorzou, MP, 2007)
"To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas."	3.73	Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. ( Piura, B; Rabinovich, A, 2005)
"Between 1992 and 1999, 13 consecutive patients with completely resected moderate- to high-grade uterine sarcoma received three cycles of adjuvant ifosfamide (1."	3.70	Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000)
" In this article we report the first case of methemoglobinemia in a patient with metastatic uterine leiomyosarcoma, after infusion of ifosfamide chemotherapy."	3.70	Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. ( Govert, JA; Hadjiliadis, D, 2000)
"The purpose of this study was to evaluate the activity of ifosfamide (isophosphamide) in patients with advanced or recurrent leiomyosarcoma not previously exposed to chemotherapy."	3.68	Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. ( Barrett, RJ; Blessing, JA; McGehee, R; Sutton, GP, 1992)
"Uterine sarcomas are rare tumors."	2.72	Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus. ( Fietkau, R; Gerber, B; Klautke, G; Kortmann, B; Reimer, T, 2006)
"The response rate of 26 patients with ovarian cancer was 30."	2.69	[Ifosfamide combination chemotherapy for advanced gynecologic malignancies]. ( Li, X; Liu, L; Wu, L, 2000)
"Of 21 patients with testicular tumors who could be evaluated, 10 (47%) achieved a CR."	2.68	High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. ( André, T; Bonnak, H; Bouleuc, C; Donsimoni, R; Esteso, A; Firmin, C; Gerota, J; Izrael, V; Lotz, JP; Merad, Z, 1995)
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies."	2.67	Gynecologic Oncology Group experience with ifosfamide. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990)
"Among gynecologic cancers, ovarian cancer is treated with chemotherapy as a routine practice."	2.41	[Gynecologic cancer-evidenced based chemotherapy]. ( Ochiai, K, 2000)
" Based on these findings, the author established a consecutive low-dose CDDP dosing method, which possibly could deliver a higher therapeutic index compared with the bolus-dosing method."	2.40	[Consecutive low-dose cisplatin-based chemotherapy for gynecologic malignancies]. ( Shimizu, Y, 1997)
"Ifosfamide was ineffective as adjuvant chemotherapy and there was aggressive tumor growth while the patient was on this regimen."	2.38	Myxoid leiomyosarcoma of the uterus. ( d'Ablaing, G; Kunzel, KE; Mills, NZ; Muderspach, LI, 1993)
"In epithelial ovarian cancer, responses were observed in eight (20%) of 41 evaluable patients, with three (7%) complete responses."	2.38	Gynecologic Oncology Group studies with ifosfamide. ( Blessing, JA; Homesley, H; Manetta, A; McGuire, W; Sutton, GP, 1992)
"Carcinosarcoma is a rare cancer, and its prognosis is poor."	1.56	Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. ( Ebata, T; Fujiwara, K; Fujiwara, Y; Hasegawa, K; Kato, T; Nishikawa, T; Noguchi, E; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K, 2020)
"Early-stage uterine sarcomas are managed by hysterectomy + bilateral salpingo-oophorectomy according to menopausal status and histology; lymphadenectomy is not indicated in patients without bulky nodes, and morcellation must be avoided."	1.56	Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). ( Aristei, C; Biondetti, PR; Cananzi, FCM; Casali, P; Ciccarone, F; Colombo, N; Comandone, A; Corvo', R; De Iaco, P; Dei Tos, AP; Donato, V; Ferrandina, G; Fiore, M; Gadducci, A; Gronchi, A; Guerriero, S; Infante, A; Lorusso, D; Odicino, F; Pirronti, T; Quagliuolo, V; Sanfilippo, R; Scambia, G; Testa, AC; Zannoni, GF, 2020)
"Uterine mullerian adenosarcoma is a rare tumor without specific clinical symptoms and signs."	1.36	[Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases]. ( Guo, LN; Han, XY; Huang, HF; Pan, LY; Sheng, K; Wan, XR; Xiang, Y, 2010)
"A case of uterine rhabdomyosarcoma is presented."	1.31	Rhabdomyosarcoma of the corpus of the uterus: a case report. ( Moerman, PH; Scheidt, P; Vergote, I, 2000)
" So we compared VAC protocol and ifosfamiide for toxic effects."	1.30	Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). ( Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998)
"The authors report a case of encephalopathy after treatment with ifosfamide treated by a methylene blue infusion."	1.29	[Treatment of ifosfamide induced encephalopathy with methylene-blue]. ( Dreyfus, G; Eftekari, P; Ferrero, JM; Largillier, R; Namer, M, 1995)
"Ifosfamide alone was given as a 24-h infusion at doses ranging from 5 to 7."	1.28	Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma. ( Hawkins, RE; Mansi, JL; Wiltshaw, E, 1990)
"Ifosfamide (IFX) has activity in a number of gynaecological malignancies and was selected for evaluation in this disease."	1.28	A phase II study of ifosfamide in endometrial cancer. ( Barton, C; Blackledge, G; Buxton, EJ; Meanwell, CA; Mould, JJ, 1990)
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies."	1.28	Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1989)
"Ifosfamide and mesna were administered to 77 patients with advanced malignancies."	1.27	Prediction of ifosfamide/mesna associated encephalopathy. ( Blackledge, G; Blake, AE; Honigsberger, L; Kelly, KA; Meanwell, CA, 1986)

Research

Studies (76)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Duration of Progression-free Survival

Timeframe	Studies, this research(%)	All Research%
pre-1990	9 (11.84)	18.7374
1990's	20 (26.32)	18.2507
2000's	25 (32.89)	29.6817
2010's	17 (22.37)	24.3611
2020's	5 (6.58)	2.80

Authors	Studies
Su, MH	1
Wu, HH	1
Huang, HY	1
Lee, NR	1
Chang, WH	1
Lin, SC	1
Chen, YJ	1
Wang, PH	3
Powell, MA	1
Filiaci, VL	1
Hensley, ML	2
Huang, HQ	1
Moore, KN	1
Tewari, KS	1
Copeland, LJ	1
Secord, AA	2
Mutch, DG	1
Santin, A	1
Warshal, DP	1
Spirtos, NM	1
DiSilvestro, PA	1
Ioffe, OB	2
Miller, DS	1
Yang, ST	1
Ebata, T	1
Yonemori, K	1
Nishikawa, T	2
Sudo, K	1
Shimomura, A	1
Noguchi, E	1
Fujiwara, Y	1
Kato, T	1
Hasegawa, K	2
Fujiwara, K	4
Tamura, K	1
Ferrandina, G	1
Aristei, C	1
Biondetti, PR	1
Cananzi, FCM	1
Casali, P	1
Ciccarone, F	1
Colombo, N	2
Comandone, A	1
Corvo', R	1
De Iaco, P	1
Dei Tos, AP	1
Donato, V	1
Fiore, M	1
Gadducci, A	2
Gronchi, A	1
Guerriero, S	1
Infante, A	1
Odicino, F	1
Pirronti, T	1
Quagliuolo, V	1
Sanfilippo, R	1
Testa, AC	1
Zannoni, GF	1
Scambia, G	1
Lorusso, D	2
Assi, T	1
El Rassy, E	1
Abi-Tayeh, G	1
Sader-Ghorra, C	1
Abadjian, G	1
Eid, R	1
Moussa, T	1
Farhat, F	1
Kattan, J	1
Galaal, K	2
van der Heijden, E	1
Godfrey, K	2
Naik, R	2
Kucukmetin, A	2
Bryant, A	2
Das, N	1
Lopes, AD	1
Mancari, R	1
Signorelli, M	1
Carinelli, S	1
De Ponti, E	1
Sesana, S	1
Corso, S	1
Chiappa, V	1
Lissoni, AA	1
Martinelli, F	1
Mancini, M	1
Sarno, I	1
Ditto, A	1
Raspagliesi, F	1
Hadoux, J	1
Rey, A	2
Duvillard, P	2
Lhommé, C	2
Balleyguier, C	1
Haie-Meder, C	2
Morice, P	1
Tazi, Y	1
Leary, A	1
Larue, C	1
Pautier, P	2
Grignani, G	1
Martín-Broto, J	1
Schuler, M	1
Reichardt, P	1
Dandamudi, RK	1
Aslam, S	1
Walji, N	1
El-Modir, A	1
Fernando, I	1
Dickson, EL	1
Vogel, RI	1
Gehrig, PA	1
Pierce, S	1
Havrilesky, L	1
Dottino, J	1
Fader, AN	1
Ricci, S	1
Geller, MA	1
Matsuo, K	1
Takazawa, Y	1
Ross, MS	1
Elishaev, E	1
Podzielinski, I	1
Yunokawa, M	1
Sheridan, TB	1
Bush, SH	1
Klobocista, MM	1
Blake, EA	1
Takano, T	1
Matsuzaki, S	1
Baba, T	1
Satoh, S	1
Shida, M	1
Ikeda, Y	1
Adachi, S	1
Yokoyama, T	1
Takekuma, M	1
Hazama, Y	1
Kadogami, D	1
Moffitt, MN	1
Takeuchi, S	1
Nishimura, M	1
Iwasaki, K	1
Ushioda, N	1
Johnson, MS	1
Yoshida, M	1
Hakam, A	1
Li, SW	1
Richmond, AM	1
Machida, H	1
Mhawech-Fauceglia, P	1
Ueda, Y	1
Yoshino, K	1
Yamaguchi, K	1
Oishi, T	1
Kajiwara, H	1
Yasuda, M	1
Kawana, K	1
Suda, K	1
Miyake, TM	1
Moriya, T	1
Yuba, Y	1
Morgan, T	1
Fukagawa, T	1
Wakatsuki, A	1
Sugiyama, T	1
Pejovic, T	1
Nagano, T	1
Shimoya, K	1
Andoh, M	1
Shiki, Y	1
Enomoto, T	1
Sasaki, T	1
Mikami, M	1
Shimada, M	1
Konishi, I	1
Kimura, T	1
Post, MD	1
Shahzad, MM	1
Im, DD	1
Yoshida, H	1
Omatsu, K	1
Ueland, FR	2
Kelley, JL	1
Karabakhtsian, RG	1
Roman, LD	1
Abu-Khalaf, MM	1
Raza, MA	1
Hatzis, C	1
Wang, H	1
Lin, K	1
Higgins, S	1
Ratner, E	1
Silasi, DA	1
Azodi, M	1
Rutherford, TJ	1
Santin, AD	1
Schwartz, PE	1
Higgins, SC	1
Zakashansky, K	1
Bovbjerg, DH	1
Hagopian, G	1
Makker, V	1
Abu-Rustum, NR	1
Alektiar, KM	1
Aghajanian, CA	1
Zhou, Q	1
Iasonos, A	1
Han, XY	1
Xiang, Y	1
Guo, LN	1
Sheng, K	1
Wan, XR	1
Huang, HF	1
Pan, LY	1
Liu, YL	1
Tsai, SH	1
Chang, FW	1
Yu, MH	1
Minobe, S	1
Todo, Y	1
Suzuki, Y	1
Aoyagi, Y	1
Umazume, T	1
Okamoto, K	1
Kato, H	1
Einstein, MH	1
Klobocista, M	1
Hou, JY	1
Lee, S	1
Mutyala, S	1
Mehta, K	1
Reimers, LL	1
Kuo, DY	1
Huang, GS	1
Goldberg, GL	1
Chang, CC	1
Wu, CC	1
Floquet, A	1
Gladieff, L	1
Bompas, E	1
Ray-Coquard, I	1
Piperno-Neumann, S	1
Selle, F	2
Guillemet, C	1
Weber, B	1
Largillier, R	2
Bertucci, F	1
Opinel, P	1
Duffaud, F	1
Reynaud-Bougnoux, A	1
Delcambre, C	1
Isambert, N	1
Kerbrat, P	1
Netter-Pinon, G	1
Pinto, N	1
Ramondetta, LM	2
Burke, TW	1
Jhingran, A	2
Schmandt, R	1
Bevers, MW	1
Wolf, JK	1
Levenback, CF	1
Broaddus, R	1
Sutton, G	3
Kauderer, J	1
Carson, LF	1
Lentz, SS	2
Whitney, CW	1
Gallion, H	1
Dusenbery, KE	1
Potish, RA	1
Argenta, PA	1
Judson, PL	1
Piura, B	1
Rabinovich, A	1
Jeon, IS	1
Lee, SM	1
Ruiz Tovar, J	1
Reguero Callejas, ME	1
Arano Bermejo, JI	1
Capote Armas, LF	1
González-Palacios Martínez, F	1
Cabañas Navarro, L	1
Kortmann, B	1
Reimer, T	1
Gerber, B	1
Klautke, G	1
Fietkau, R	1
Moreno Antón, F	1
Casado Herraez, A	1
Puente Vázquez, J	1
Gómez Díaz, R	1
Aragoncillo, P	1
Díaz-Rubio García, E	1
Homesley, HD	3
Filiaci, V	1
Markman, M	2
Bitterman, P	1
Eaton, L	1
Kilgore, LC	1
Monk, BJ	1
Skubitz, KM	1
Manivel, JC	1
Papadimitriou, CA	1
Zorzou, MP	1
Markaki, S	1
Rodolakis, A	1
Voulgaris, Z	1
Bozas, G	1
Kastritis, E	1
Bamias, A	1
Gika, D	1
Dimopoulos, MA	1
Wolfson, AH	1
Brady, MF	1
Rocereto, T	1
Mannel, RS	1
Lee, YC	1
Futoran, RJ	1
Cohn, DE	1
Brunello, A	1
Basso, U	1
Rossi, E	1
Stefani, M	1
Ghiotto, C	1
Marino, D	1
Crivellari, G	1
Monfardini, S	1
Kohno, I	1
Kazuta, M	1
Miyao, J	1
Kunimi, N	1
Kawamoto, M	1
Tanimura, T	1
Sekiba, K	1
Ferrero, JM	1
Eftekari, P	1
Dreyfus, G	1
Namer, M	1
Garris, PD	1
Gallup, DG	1
Melton, K	1
Lotz, JP	2
André, T	2
Donsimoni, R	1
Firmin, C	1
Bouleuc, C	2
Bonnak, H	1
Merad, Z	1
Esteso, A	1
Gerota, J	1
Izrael, V	2
Kunzel, KE	1
Mills, NZ	1
Muderspach, LI	1
d'Ablaing, G	1
Droz, JP	1
Biron, P	1
Blessing, JA	6
Malfetano, JH	1
Psikakos, G	1
Papanicolaou, A	1
Boutis, L	1
Goutzioulis, M	1
Makedos, G	1
Papanicolaou, N	1
Péne, F	1
Gattegno, B	1
Bazelly, B	1
Houry, S	1
Chapiro, J	1
Gligorov, J	1
Mollenkopf, A	1
du Bois, A	1
Meerpohl, HG	1
Shimizu, Y	1
van Besien, K	1
Verschraegen, C	1
Mehra, R	1
Giralt, S	1
Kudelka, AP	1
Edwards, CL	1
Piamsonboom, S	1
Termrungruanglert, W	1
Champlin, R	1
Kavanagh, JJ	1
Yuan, CC	1
Chao, HT	1
Wang, HM	1
Hirota, Y	2
Miyamura, K	1
Hayata, T	1
Miyakawa, I	1
Simşek, T	1
Uner, M	1
Trak, B	1
Erman, O	1
Zorlu, GC	1
Ochiai, K	1
Kushner, DM	1
Webster, KD	1
Belinson, JL	1
Rybicki, LA	1
Kennedy, AW	1
Hadjiliadis, D	1
Govert, JA	1
Scheidt, P	1
Moerman, PH	1
Vergote, I	1
Edmonson, JH	1
Brunetto, VL	1
Kilgore, L	1
Soper, JT	1
McGehee, R	2
Olt, G	1
Sorosky, J	1
Hsiu, JG	1
Tsuda, H	1
Maed, K	1
Hashiguchi, Y	1
Inoue, T	1
Kobayashi, Y	1
Umesaki, N	1
Yamamoto, K	1
Li, X	1
Liu, L	1
Wu, L	1
Postovsky, S	1
Beck, D	1
Ben-Izhak, O	1
Arush, MW	1
Sutton, GP	5
Manetta, A	1
Homesley, H	1
McGuire, W	1
Barrett, RJ	1
Hamaguchi, K	1
Komai, K	1
Sakihama, H	1
Okura, N	1
Nagasue, N	2
Nishida, T	2
Yakushiji, M	2
Photopulos, G	3
Berman, ML	2
Hawkins, RE	1
Wiltshaw, E	1
Mansi, JL	1
Barton, C	1
Buxton, EJ	1
Blackledge, G	3
Mould, JJ	2
Meanwell, CA	3
Rosenshein, N	1
DiSaia, PJ	1
Blake, AE	2
Latief, TN	1
Blake, DR	1
Shaw, IC	1
Honigsberger, L	2
Spooner, D	1
Williams, AC	1
Kelly, KA	1
Kishi, N	1
Imaishi, K	1
Tateno, N	1
Matsumura, T	1
Loehrer, PJ	1
Einhorn, LH	1
Williams, SD	1
Sawada, M	1
Inagaki, M	1
Hongo, J	1
Ozaki, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, P[NCT00954174]	Phase 3	637 participants (Actual)	Interventional	2009-08-17	Active, not recruiting
Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)[NCT02993705]	Phase 2	45 participants (Actual)	Interventional	2017-02-22	Completed
"A Pilot Phase II Trial of Adjuvant Radiation Therapy Sandwiched Between Ifosfamide in Patients With Mixed Mesodermal Tumors"[NCT00231842]	Phase 2	30 participants (Actual)	Interventional	2003-02-28	Completed
A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus[NCT00003128]	Phase 3	166 participants (Anticipated)	Interventional	1997-11-30	Completed
A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus[NCT00002546]	Phase 3	216 participants (Anticipated)	Interventional	1993-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Measured in months from randomization to last contact or the earlier of the date of progression or death. (NCT00954174)
Timeframe: Approximately 9 years and 7 months

Overall Survival

Intervention	months (Median)
Regimen I - Uterine Carcinsarcoma Subjects	16.3
Regimen II - Uterine Carcinsarcoma Subjects	11.7
Regimen III - Non-uterine Carcinsarcoma Subjects	14.6
Regimen IV - Non-uterine Carcinsarcoma Subjects	10.3

Measured in months from randomization to last contact or death. Primary analysis was restricted to the eligible uterine carcinosarcoma cohort. (NCT00954174)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 115 months.

Patient Reported Peripheral Neuropathy Symptoms - Baseline

Intervention	months (Median)
Regimen I- Uterine Carcinsarcoma Subjects	37.3
Regimen II - Uterine Carcinsarcoma Subjects	29

Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 11 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). . The Ntx score ranges 0-44 with a large score suggesting less peripheral neuropathy symptoms. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Baseline (Pre cycle 1)

Patient-Reported Quality of Life (QOL) - Baseline

Intervention	units on a scale-baseline (Mean)
Regimen I - Uterine and Non-Uterine Subjects	40.2
Regimen II - Uterine and Non-Uterine Subjects	41.0

Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-En TOI). The FACT-En TOI is a scale for assessing general QOL of endometrial cancer patients. The FACT-En TOI score ranges 0-120 with a large score suggesting better QOL. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Baseline - Prior to study treatment

Incidence of Adverse Events as Assessed by CTCAE Version 3.0

Intervention	units on a scale (time point) (Mean)
Regimen I - Uterine and Non-Uterine Subjects	96.2
Regimen II - Uterine and Non-Uterine Subjects	97.5

Maximum grade experienced among all treated and eligible patients. The grades are described by severity. Grade 1 is the lowest (most mild) and Grade 5 being death (most severe). Adverse events were analyzed across cohorts since disease site was considered independent of AEs. (NCT00954174)
Timeframe: Patients were assessed for adverse events during active protocol treatment and up to 30 days after the last cycle of treatment on the protocol.

Patient Reported Quality of Life (QOL) - Post Baseline

Intervention	Participants (Count of Participants)
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Regimen I - Uterine and Non-Uterine Subjects	3	22	107	130	6
Regimen II - All Uterine and Non-Uterine Subjects	3	80	97	61	3

Patient-reported Peripheral Neuropathy Symptoms - Post Baseline

Intervention	units on a scale (time point) (Least Squares Mean)
	Pre-cycle 3	Pree-cycle 6	30 weeks post cycle 1
Regimen I - Uterine and Non-Uterine Subjects	93.3	91.6	98.0
Regimen II - Uterine and Non-Uterine Subjects	93.3	91.6	97.6

Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 11 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). The Ntx score ranges 0-44 with a large score suggesting less peripheral neuropathy symptoms.Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Prior to cycle 3, Prior to cycle 6, 30 weeks post cycle 1

Cycles With Hematologic Toxicities

Intervention	units on a scale (Least Squares Mean)
	Prior to cycle 3	Prior to cycle 6	30 weeks post cycle 1
Regimen I - Uterine and Non-Uterine Subjects	37.2	34.1	34.8
Regimen II - Uterine and Non-Uterine Subjects	37.0	34.2	34.9

Out of 162 planned cycles, a total of 138 cycles (85%) were administered. Number of cycles during which participants with grades 3 and 4 experienced hematologic toxicities are reported. Most of the toxicities were self-limiting. (NCT00231842)
Timeframe: 2 years

Intervention	Cycles (Number)
	Neutropenia	Anemia	Thrombocytopenia
Grade 3 Toxicity	11	6	6
Grade 4 Toxicity	14	0	2

Article	Year
Chemotherapy-induced differentiation to cure botryoid rhabdomyosarcoma: a case report and review of the literature. European journal of gynaecological oncology, 2017, Volume: 38, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Dactinomycin; Desmin; F	2017
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. The Cochrane database of systematic reviews, 2013, Feb-28, Issue:2 Topics: Antineoplastic Agents, Alkylating; Carcinosarcoma; Chemotherapy, Adjuvant; Female; Humans; Ifosfamid	2013
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. The Cochrane database of systematic reviews, 2011, Jan-19, Issue:1 Topics: Antineoplastic Agents, Alkylating; Carcinosarcoma; Chemotherapy, Adjuvant; Female; Humans; Ifosfamid	2011
On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. American journal of clinical oncology, 2005, Volume: 28, Issue:3 Topics: Abdominal Neoplasms; Antineoplastic Agents; Brachytherapy; Chemotherapy, Adjuvant; Combined Modality	2005
Giant cell tumor of the uterus: case report and response to chemotherapy. BMC cancer, 2007, Mar-14, Volume: 7 Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal	2007
Myxoid leiomyosarcoma of the uterus. Gynecologic oncology, 1993, Volume: 48, Issue:2 Topics: Female; Humans; Ifosfamide; Leiomyosarcoma; Middle Aged; Mitotic Index; Uterine Neoplasms	1993
[Consecutive low-dose cisplatin-based chemotherapy for gynecologic malignancies]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin;	1997
[Gynecologic cancer-evidenced based chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Evidence-Based Medicine; Femal	2000
Secondary thyroid carcinoma after treatment for clear cell carcinoma of the uterus: case report and review of the literature. Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin;	2001
Gynecologic Oncology Group studies with ifosfamide. Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 12 Topics: Adenocarcinoma; Carcinoma; Clinical Trials, Phase II as Topic; Endometrial Neoplasms; Female; Genita	1992

Article	Year
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 03-20, Volume: 40, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Sur	2022
Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecologic oncology, 2012, Volume: 124, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother	2012
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4 Topics: Adult; Aged; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Do	2013
A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. Gynecologic oncology, 2003, Volume: 90, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfamide;	2003
Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecologic oncology, 2005, Volume: 96, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chem	2005
Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2006, Volume: 182, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Respons	2006
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-10, Volume: 25, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin	2007
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-10, Volume: 25, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin	2007
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-10, Volume: 25, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin	2007
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-10, Volume: 25, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin	2007
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecologic oncology, 2007, Volume: 107, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap	2007
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecologic oncology, 2007, Volume: 107, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap	2007
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecologic oncology, 2007, Volume: 107, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap	2007
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecologic oncology, 2007, Volume: 107, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap	2007
High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer, 1995, Feb-01, Volume: 75, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb	1995
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecologic oncology, 1996, Volume: 62, Issue:2 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined	1996
The ICE regimen (ifosfamide, carboplatin, etoposide) for the treatment of germ-cell tumors and metastatic trophoblastic disease. Bone marrow transplantation, 1996, Volume: 18 Suppl 1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th	1996
A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecologic oncology, 2000, Volume: 79, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother	2000
[Ifosfamide combination chemotherapy for advanced gynecologic malignancies]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2000, Volume: 22, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; I	2000
Gynecologic Oncology Group experience with ifosfamide. Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy;	1990

Article	Year
Comparing paclitaxel-platinum with ifosfamide-platinum as the front-line chemotherapy for patients with advanced-stage uterine carcinosarcoma. Journal of the Chinese Medical Association : JCMA, 2022, 02-01, Volume: 85, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Femal	2022
Abandon ifosfamide-based regimen and use paclitaxel-carboplatin regimen for the treatment of uterine carcinosarcoma. Journal of the Chinese Medical Association : JCMA, 2022, 05-01, Volume: 85, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Female; Humans; Ifosfam	2022
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. Oncology, 2020, Volume: 98, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Docetaxel;	2020
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). European journal of cancer (Oxford, England : 1990), 2020, Volume: 139 Topics: Adenosarcoma; Anthracyclines; Antineoplastic Agents; Chemotherapy, Adjuvant; Consensus; Dacarbazine;	2020
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients. Gynecologic oncology, 2014, Volume: 133, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemothera	2014
Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino	2014
Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin; Combined Modali	2015
Trabectedin clinical cases: use according to indication in diverse clinical scenarios. Future oncology (London, England), 2015, Volume: 11, Issue:11 Suppl Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; C	2015
Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna. Anticancer research, 2015, Volume: 35, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma	2015
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. Gynecologic oncology, 2015, Volume: 139, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma	2015
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:7 Topics: Adult; Aged; Carcinoma; Carcinosarcoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Human	2016
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. European journal of gynaecological oncology, 2016, Volume: 37, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherap	2016
Unexpected vomiting in a woman contemplating a second course of chemotherapy for carcinosarcoma of the uterus. Journal of pain and symptom management, 2008, Volume: 36, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; F	2008
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecologic oncology, 2008, Volume: 111, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Diseas	2008
[Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:1 Topics: Adenosarcoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv	2010
Ifosfamide-induced encephalopathy in patients with uterine sarcoma. Taiwanese journal of obstetrics & gynecology, 2010, Volume: 49, Issue:1 Topics: Aged; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Methylene Blue; Middle Aged; Ne	2010
Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases. The journal of obstetrics and gynaecology research, 2011, Volume: 37, Issue:6 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubic	2011
Beau's lines. QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Female; Humans; Ifosfamide; Middle A	2013
Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. European journal of gynaecological oncology, 2005, Volume: 26, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Mesn	2005
Multimodal treatment using surgery, radiotherapy, and chemotherapy in a patient with a perivascular epithelioid cell tumor of the uterus. Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Doxorubicin; Epith	2005
Malignant mixed Mullerian tumors. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemo	2006
Cardiac metastasis from uterine leiomyosarcoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidin	2006
Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience. European journal of gynaecological oncology, 2007, Volume: 28, Issue:2 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined	2007
Eleven years: the long and winding road. Gynecologic oncology, 2007, Volume: 107, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; C	2007
Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature. Drugs & aging, 2007, Volume: 24, Issue:11 Topics: Abdominal Neoplasms; Aged; Antidotes; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che	2007
[Clinical studies of ifosfamide for gynecological malignancies]. Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:5 Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Evaluation; Female; Humans; I	1983
[Treatment of ifosfamide induced encephalopathy with methylene-blue]. Bulletin du cancer, 1995, Volume: 82, Issue:7 Topics: Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Female; Humans; Ifosfamide; Methylene Blue;	1995
Long-term remission of previously resistant choriocarcinoma with a combination of etoposide, ifosfamide, and cisplatin. Gynecologic oncology, 1995, Volume: 57, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Drug Resistance;	1995
High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer, 1995, Jul-01, Volume: 76, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com	1995
The use of combined chemotherapy for the treatment of advanced sarcoma of the uterus. European journal of gynaecological oncology, 1996, Volume: 17, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C	1996
[Sequential course and prospective management of ifosfamide-induced multi-organ toxicity]. Geburtshilfe und Frauenheilkunde, 1996, Volume: 56, Issue:10 Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modal	1996
Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. Gynecologic oncology, 1997, Volume: 65, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality	1997
The VIP regimen effective treatment to refractory choriocarcinoma: a case report. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1997, Volume: 59, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etoposide; Female	1997
Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide. Gynecologic and obstetric investigation, 1997, Volume: 44, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans; Ifosf	1997
Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). European journal of gynaecological oncology, 1998, Volume: 19, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad	1998
Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Gynecologic oncology, 2000, Volume: 78, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide;	2000
Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. Chest, 2000, Volume: 118, Issue:4 Topics: Antineoplastic Agents, Alkylating; Biomarkers; Diagnosis, Differential; Female; Humans; Ifosfamide;	2000
Rhabdomyosarcoma of the corpus of the uterus: a case report. European journal of gynaecological oncology, 2000, Volume: 21, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Female; Humans; Hysterectomy; I	2000
Are we there yet? Gynecologic oncology, 2000, Volume: 79, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Female; Humans; Ifosfamid	2000
Malignant rhabdoid tumour of the uterine cervix. BJOG : an international journal of obstetrics and gynaecology, 2001, Volume: 108, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etopo	2001
Report on carcinogenesis bioassay of isophosphamide. American Industrial Hygiene Association journal, 1978, Volume: 39, Issue:6 Topics: Animals; Carcinogens; Cyclophosphamide; Cystitis; Dogs; Female; Hair; Ifosfamide; Lymphoma; Male; Ma	1978
Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. American journal of obstetrics and gynecology, 1992, Volume: 166, Issue:2 Topics: Adult; Aged; Agranulocytosis; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide	1992
Chemotherapeutic approach to uterine papillary serous carcinoma. Asia-Oceania journal of obstetrics and gynaecology, 1990, Volume: 16, Issue:4 Topics: Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Carc	1990
Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma. Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Leio	1990
A phase II study of ifosfamide in endometrial cancer. Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Ifosfamide;	1990
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Ci	1989
Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). American journal of obstetrics and gynecology, 1989, Volume: 161, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Fem	1989
Encephalopathy associated with ifosphamide/mesna therapy. Lancet (London, England), 1985, Feb-16, Volume: 1, Issue:8425 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Cyclophosphamide; Female; Humans; If	1985
Prediction of ifosfamide/mesna associated encephalopathy. European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Electroencephalography; Female; Huma	1986
A preliminary study of a combination chemotherapy with ifosfamide, adriamycin and cisplatin for endometrial carcinoma. Nihon Sanka Fujinka Gakkai zasshi, 1988, Volume: 40, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubi	1988
VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Female; Humans; Ifosfami	1986
[Ifosfamide, cisplatin, adriamycin combination chemotherapy in gynecologic cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administra	1987

ifosfamide and Cancer of the Uterus